QNCX — Quince Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662774 ·
Last close
$0.90
Market Cap
$17.66M
52W High
$3.84
52W Low
$0.79
ADV30
1,536,074
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,112,000 | 35,912,000 | 26,623,000 | 18,163,000 | 10,951,000 |
| Dec 2025 | 0 | — | -16,236,000 | -39,458,000 | 93,523,000 | 5,809,000 | 129,237,000 |
| Sep 2025 | 0 | — | -11,364,000 | -13,442,000 | 109,899,000 | 6,452,000 | 108,840,000 |
| Jun 2025 | 0 | — | -9,895,000 | -16,049,000 | 117,210,000 | 16,826,000 | 105,474,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,451,000
Investing CF
$24,329,000
Financing CF
$27,265,000
CapEx
$-352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.44
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-460,451,000
Inventory
—
Receivables
$3,622,000
ST Investments
$11,943,000
EBIT TTM
$-50,429,000
Pretax Income TTM
$-80,765,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -50,429,000 | -83,979,000 | 93,523,000 | 129,237,000 | — | -41,425,000 |
| Dec 2024 | 0 | -36,170,000 | -56,828,000 | 114,478,000 | 84,332,000 | — | -31,904,000 |
| Dec 2023 | 0 | -27,142,000 | -31,385,000 | 167,900,000 | 82,816,000 | — | -18,292,000 |
| Dec 2022 | 0 | -51,190,000 | -51,660,000 | 103,910,000 | 3,317,000 | — | -44,038,000 |
TTM Snapshot
Revenues TTM
$1,846,000
NetIncome TTM
$-16,500,000
OpCashFlow TTM
$0
Assets (Latest)
$114,478,000
Forward EPS
$-1.17
Max Pain — expiry 2026-07-17
max pain strike: $0.50 · spot: $0.90 · call oi: 10,564 · put oi: 147
Expected Move to 2026-07-17:
±$0.95
(105.20%) —
implied range
$-0.05 –
$1.85
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PASG | Passage BIO, Inc. | $17.10M | $5.33 | — |
| CVM | CEL SCI CORP | $19.22M | $1.10 | — |
| CRIS | CURIS INC | $15.83M | $0.41 | — |
| ZIVO | Zivo Bioscience, Inc. | $15.32M | $3.69 | — |
| BCDA | BioCardia, Inc. | $14.10M | $0.95 | — |
News headlines (Yahoo Finance, 1h cache)
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
2026-06-02 13:56 · Yahoo
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
2026-05-18 14:21 · Yahoo
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
2026-05-18 13:26 · Yahoo
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
2026-05-18 13:26 · Yahoo
Quince Therapeutics Settles Approximately $16.4 Million of Debt
2026-03-30 12:30 · Yahoo
BC-Most Active Stocks
2026-03-05 15:30 · Yahoo
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
2026-02-09 21:05 · Yahoo
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
2026-02-02 12:19 · Yahoo
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
2026-01-30 14:54 · Yahoo
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
2026-01-29 20:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.